OpenAI is rolling out ChatGPT Health to all U.S. users over 18 on free and paid plans, letting them link personal data from Apple Health, Epic and other platforms. The feature, tested since January amid rising health queries and a lawsuit over bad advice, still carries a disclaimer against using it for formal diagnosis.

• ChatGPT Health is now available to all US users 18+ across free and paid plans, letting them connect data from Apple Health, Epic, and similar platforms into any chat.
• Health-related queries on ChatGPT have jumped from 230 million to 300 million per week since January testing began.
• OpenAI still disclaims the tool for diagnosis or treatment, a stance relevant to a lawsuit claiming ChatGPT discouraged a Florida pastor from seeing a doctor.

Founders from the Department of Government Efficiency built SpecialOS, an AI-driven platform that automates tasks in Main Street service industries. Their first target is eldercare via Figure Health, where they’ve acquired a Texas provider, plan to open-source billing claims, and use efficiencies to boost nurse pay.

• Ex-DOGE founders launched SpecialOS to acquire and run Main Street service businesses with AI automation rather than just sell software to them
• First acquisition is Figure Health, a Texas home-health provider with 1,400 patients, where AI-driven billing/scheduling savings will fund higher nurse pay
• Figure Health will open-source its Medicare/Medicaid billing claims for public transparency
• Backed by a16z and a roster including Brian Armstrong (Coinbase), Shyam Sankar (Palantir), and several former DOGE officials, with plans to expand into other regulated, labor-intensive industries and eventually go public

The article claims AI agents can autonomously handle repetitive admin work—data entry, billing, insurance claims—for small businesses, freeing owners to serve more customers and improve work-life balance. It uses Lassie, deployed in over 700 medical practices and saving up to 190 hours of labor per month, as proof, and outlines the technical, regulatory, and go-to-market challenges in building and scaling these systems.

• A Menlo Park dentist was found logging 2,400 hours a year on admin, and typical practices spend ~$200K annually on staff for billing/scheduling/claims work
• Lassie, an autonomous admin AI agent, now runs in 700+ medical practices across 49 states, saving an average of 30 hours/month and up to 190 hours/month per office
• The founders built credibility and reliability by doing the admin work themselves (reconciling millions in claims, billing thousands of patients) and onboarding customers in person
• Results include doctors seeing more patients, leaving on time, taking vacations, and one crediting the tool with saving his marriage

A Stat survey of nearly 1,000 NIH grantees shows 27% got no funding back after a $32 billion cut, while only 35% saw full restoration. Experts warn the loss slowed careers, pushed talent to industry or abroad, and could undercut future breakthroughs and public health.

• Only 35% of nearly 1,000 surveyed NIH grantees got full funding restored a year after $32 billion in cuts; 27% got nothing back
• The instability is pushing early-career researchers out of academic research entirely—into industry or abroad
• Knudsen ties steady NIH funding to a 34% drop in cancer deaths since 1991 and warns cuts will favor "safer" projects over bold clinical trials
• Some see it as a forced "reset" that could push NIH to redesign how it allocates grants, though rebuilding lost infrastructure will take years

This article explains how healthcare organizations can get a HIPAA-compliant Business Associate Agreement with OpenAI to process protected health information via the API. Email baa@openai.com with your company details and use case; most requests are approved within a few business days. If your request is denied, you can seek reconsideration through your sales contact.

• Emailing baa@openai.com with company details and use case gets most BAA requests approved within a few business days.
• Denied requests can only be reconsidered if you already have an OpenAI sales rep or account director to escalate through.
• Nearly all API services are covered under the BAA (exceptions listed in the platform docs), and no enterprise agreement is required to get one.

Pete McCanna argues that most health systems are built to fill capacity instead of creating value for patients and is overhauling Baylor Scott & White around “customers” rather than “patients.” He outlines how loyalty-driven, sometimes loss-leading services, AI-powered differentiation, and rewritten healthcare laws fit into a model that prioritizes access, personalization, and long-term trust over short-term profit.

• McCanna reframes patients as "customers" to force a shift from filling capacity to actually serving needs, restructuring care around conditions instead of departments across 55 hospitals and 1,300 access points
• He's willing to run loss-leading services (easier access, personalized follow-up) betting that loyalty pays off long-term through retention and referrals
• AI is being deployed for customer-facing differentiation—tailored treatment plans, predictive risk alerts, digital check-ins—not just cost-cutting
• He dismisses the "payvider" model as harder than advertised due to regulatory and cultural clashes, and wants three federal healthcare laws rewritten (touching payment, scope-of-practice, and data-sharing) to make customer-centric care viable

This article profiles eight healthcare services companies using AI across their care stacks to cut costs, speed up treatment, and boost patient engagement. From smarter caregiver scheduling at Honor to AI-driven patient outreach at Cityblock, each example shows measurable improvements in outcomes, efficiency, or retention. The piece argues that service-focused models with embedded AI have a durable edge over pure software plays.

• Honor cut home-caregiver churn from an industry-standard 85% annually down to the mid-30s by using AI to match schedules to caregivers' actual behavior, not just stated preferences.
• Ro's AI triage tool slashed median patient response time from under 2 hours to 33 minutes, answering urgent messages in 26 minutes or less.
• Aledade's EHR Overlay is live in 85%+ of eligible practices and made diabetic patients 40% more likely to fill statin prescriptions within two weeks.
• The article's core argument: embedding AI into service delivery (not just selling standalone software) is what's driving durable, measurable gains in cost, speed, and engagement across these companies.

Prompt Opinion lets healthcare organizations plug in interoperable AI agents, tools, and standards into real workflows. It uses MCP, A2A, and FHIR to connect EHRs, policies, and data, turning standalone agents into production-ready tasks like prior authorizations, trial matching, and population health analyses.

• Prompt Opinion connects healthcare AI agents to real EHRs, policies, and data using open standards (MCP, A2A, FHIR) instead of leaving them as isolated pilots.
• The platform targets concrete production tasks—prior authorizations, trial matching, population health gap analysis, chart summarization—not just demos.
• Builders can publish agents once (via TypeScript/Python reference code) and reach every customer, while healthcare orgs get turnkey, audited, compliant integrations from day one.
• It's live in beta with an "Agents Assemble Challenge" recruiting developers to build agents that output real deliverables like documents, tables, or transactions.

Americans spend more on healthcare than any other country, largely because the U.S. pays far higher prices for the same surgeries, drugs and medical services. Increased use of costly hospital care and new weight-loss medications has driven spending even higher.

• U.S. families pay about $27,000 a year on average for health insurance.
• Identical procedures (hip replacements, MRIs) and even generic drugs cost far more in the U.S. than in other countries.
• Rising hospital utilization is pushing spending higher.
• New weight-loss drugs, costing thousands per month, are a significant driver of increased healthcare spending.

Shiv Rao, cardiologist-turned-CEO of Abridge, explains why the company focuses on doctor-patient conversations rather than just notes, how it builds 70–80% of its own AI models, and why it retains full control despite raising $800 million. He also outlines Abridge’s edge over dozens of rival scribes, its new real-time prior-auth tool, and how it navigates liability and regulation.

• Abridge builds 70-80% of its own AI models in-house rather than relying on public/frontier models, reserving those for non-critical tasks
• Despite raising $800 million, Shiv Rao and co-founders retain full control and avoid strategic investors with board seats to prevent conflicts of interest
• The company differentiates itself from ~126 competing AI scribes by focusing on the full clinical conversation (not just notes) as the foundation for downstream workflows like billing and orders
• Abridge operates in 250+ health systems at a $5.3 billion valuation, targeting over a million recorded patient encounters per day this year

Sutter Health and Allina Health have signed a Letter of Intent for Allina Health to join Sutter, creating a combined nonprofit health system. This partnership aims to enhance patient access, affordability, and care quality through technological advancements and expanded services in Minnesota and western Wisconsin.

• Sutter Health and Allina Health signed a Letter of Intent to merge, with Allina becoming Sutter's Upper Midwest Division while keeping its Minneapolis headquarters and brand
• The deal includes a $2 billion investment in Minnesota and Wisconsin for expanded facilities, AI tools to reduce administrative burden, and better patient scheduling
• The combined system would span 39 hospitals and 400 care sites, employ 88,000 workers and 18,000 physicians, and serve over 5 million patients
• Merger is expected to close by end of 2026 pending regulatory approval, with Warner Thomas as CEO and Lisa Shannon continuing to lead Allina Health

Mark Cuban discusses his approach to fixing healthcare, emphasizing transparency in drug pricing and the need to dismantle the influence of pharmacy benefit managers. He advocates for cash pricing legislation and supports the Break Up Big Medicine Act to separate insurance companies from their non-insurance interests.

• The Dallas Mavericks paid $169,000 for generic drugs that would have cost just $19,000 through Cuban's Cost Plus company.
• Cuban backs the Break Up Big Medicine Act, which would force insurance companies to divest their PBM arms.
• He wants legislation requiring cash drug payments to count toward insurance deductibles, plus state-controlled formularies to curb PBM power.
• He gave TrumpRx an "A-" and says FDA application costs, not tariffs, are the real barrier to bringing generic manufacturing to the US.

The article discusses the Centers for Medicare & Medicaid Services (CMS) efforts to transition healthcare providers and insurers away from outdated, manual methods of sharing patient information. This initiative aims to streamline data exchange and improve efficiency within the healthcare system.

• The number of ACA marketplace customers paying over $6,000 a year in premiums doubled in 2026.
• The summary provided is mismatched with the title—it describes a CMS data-sharing/EHR modernization initiative rather than ACA premium costs.

This article highlights the legal risks of Pharmacy Benefit Manager (PBM) contracts for employers due to new fiduciary duties. It introduces RootTrust, a platform that analyzes these contracts, providing clarity and compliance to protect companies from financial and legal pitfalls.

• New fiduciary duty laws are shifting legal liability for opaque PBM contracts from PBMs onto employers themselves.
• RootTrust uses AI to translate dense PBM contract legalese into risk scores and flag problematic clauses.
• It positions itself as an independent auditor rather than a PBM competitor, monetizing via consulting firm subscriptions and one-time fees for self-insured employers.
• Its data moat comes from accumulating analyzed contracts over time, improving its ability to detect risky contract language.

The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.

• FDA is shifting the default Phase 3 requirement from two pivotal trials to one, potentially cutting years and money off the $2.6 billion, 10-15 year drug development process.
• The impact will be uneven: urgent diseases like ALS could benefit from faster single-trial approval, while high-placebo-response conditions like pain may struggle to prove efficacy with just one study.
• Smaller biotechs with limited funding but multiple drugs in development stand to gain the most from reduced trial requirements.
• FDA plans to offset reduced pre-approval testing with continued postmarket surveillance and new tools like AI and real-world data to maintain safety and precision.

The FDA plans to allow drug approvals based on a single clinical trial instead of the traditional two. Commissioner Marty Makary stated that this change aims to streamline the approval process while maintaining safety and efficacy standards. Some exceptions will still apply, where two trials may be required.

• FDA will now generally accept a single clinical trial for drug approval instead of the traditional two
• Two trials will still be required in certain (unspecified) cases
• Makary argues a well-designed, controlled single trial can match the statistical power of two trials
• Many drugmakers were already submitting only one pivotal trial, so the policy formalizes existing practice

Hospital-at-home care is facing significant challenges in managing medical waste, as existing disposal regulations do not fully apply to at-home settings. Healthcare professionals report difficulties with proper waste management, which raises safety concerns for patients and caregivers. As the model continues to grow, there is a pressing need for proactive regulation and effective waste disposal solutions.

• 373 hospitals were approved for hospital-at-home programs as of January 2023, showing rapid growth of a model with no matching waste rules.
• A 2023 report found managing pharmaceutical and medical waste was healthcare workers' top concern in home care, with most wanting more resources to handle it.
• Patients themselves are often left responsible for disposing of hazardous items like sharps and pharmaceuticals, since hospital-grade disposal regulations don't apply at home.
• A 2024 CMS study found at-home care much cheaper than hospital care, fueling calls for investment in a "reverse supply chain" to safely collect and process medical waste from homes.

The article discusses the importance of data activation in enhancing the performance of large language models (LLMs), particularly in the healthcare sector. It highlights recent advancements in transforming structured medical data into usable formats for LLMs, emphasizing the need for effective reasoning methods to fully leverage the potential of healthcare data.

• Having proprietary data is no longer enough—the real advantage comes from "activating" it into forms LLMs can actually use before competitors catch up
• Tables2Traces converts structured medical data into reasoning traces via contrastive reasoning, notably boosting LLM performance on medical tasks
• Doctors have questioned the fidelity of these synthetic reasoning traces, and gains so far appear mainly in weaker models, raising doubts about scalability
• Despite heavy healthcare-focused LLM investment from OpenAI and Anthropic, the field is fragmented and the best method for transforming healthcare data (knowledge graphs, ontology grounding, etc.) is still unsettled

The article provides official guidance on how the Health Insurance Portability and Accountability Act (HIPAA) applies to online tracking technologies. It emphasizes the importance of protecting patient privacy and ensuring compliance when using digital tools for tracking purposes. The content is aimed at professionals navigating these regulations.

• Tracking tech on healthcare websites/apps (cookies, web beacons, pixels) can transmit PHI to third parties like Google or Meta, triggering HIPAA obligations even without login credentials
• Covered entities must have a valid HIPAA authorization or a Business Associate Agreement with tracking vendors before allowing them access to PHI, not just a general privacy policy disclosure
• IP addresses combined with visits to health-related pages can count as PHI, so even "de-identified" or aggregate analytics tools carry compliance risk
• Organizations face liability exposure if third-party trackers disclose PHI without proper safeguards, making an audit of existing tracking tools and vendor contracts a practical necessity

Claude for Healthcare is now available, providing HIPAA-compliant tools for healthcare providers and patients to improve medical processes such as prior authorizations and claims appeals. Additionally, Claude for Life Sciences has expanded its capabilities to better support clinical trial operations and regulatory submissions. These advancements aim to streamline healthcare tasks and enhance the quality of patient care.

• Claude for Healthcare launches with HIPAA-compliant tools plus connectors to CMS Coverage Database, ICD-10, and the NPI Registry for faster data retrieval and report generation
• New Agent Skills target prior authorization reviews and interoperability, letting organizations customize workflows to speed approvals and support claims appeals
• Opus 4.5's improved medical/scientific performance extends Claude's use into ambient scribing, clinical decision support, and personal health data summarization for individual users
• Claude for Life Sciences adds integrations with Medidata and ClinicalTrials.gov to support clinical trial patient recruitment, protocol design, and access to historical trial data

Many users are unaware that conversations with consumer AI about health issues lack legal protections, unlike communications with licensed healthcare providers. This article highlights the risks of disclosing personal health information to AI, which can be subpoenaed in legal situations, exposing users to potential misuse of their private data. It emphasizes the importance of understanding what privileges are lost when opting for AI assistance over traditional healthcare communications.

• Conversations with AI like ChatGPT or Claude aren't protected by legal privilege, unlike those with doctors or therapists, meaning they can be subpoenaed and used in court
• A wrongful death lawsuit already involved private mental health conversations being submitted as evidence
• OpenAI admits it doesn't train on user chats but authorized staff can still access them, leaving data vulnerable to legal requests
• Surveys show many users mistakenly believe AI chats carry the same confidentiality as conversations with doctors or lawyers

ChatGPT Health may be a marketing strategy rather than a genuine innovation, potentially allowing tech giants to dominate the healthcare sector. The article questions OpenAI's claims of enhanced security and adherence to HIPAA standards, drawing parallels to past controversies with data privacy in the tech industry.

• OpenAI's claims of HIPAA compliance and enhanced security for ChatGPT Health may be more marketing spin than substantive privacy protection
• The move could let a tech giant leverage user trust to gain a dominant foothold in the healthcare data market
• The situation echoes past tech industry controversies over data privacy, raising skepticism about the sincerity of OpenAI's promises

Multimodal vector databases like ApertureDB are revolutionizing how industries manage and verify data, particularly in healthcare advertising. By integrating various data types and employing AI tools, these databases enhance compliance by detecting omissions in marketing content, ensuring that critical information is accurately conveyed to patients.

• ApertureDB combines multimodal vector search with AI to flag missing required information (like side effects or risks) in healthcare marketing content.
• The system helps compliance teams catch omissions before ads reach patients, reducing regulatory and safety risks.

Mark Cuban and Optum CEO Patrick Conway engaged in a heated discussion about drug prices and pharmacy benefit managers, highlighting their differing views on how to reform the healthcare system. Cuban argued for breaking up large insurance companies and criticized the lack of transparency in PBM contracts, while Conway emphasized the need to tackle high hospital and pharmaceutical costs. Both acknowledged the other's contributions but remained divided on the root causes of high drug prices and solutions.

• Cuban challenged Conway to name a specific Optum customer he could call to verify claims about PBM contract transparency
• Cuban advocates breaking up large insurance companies as a fix, blaming opaque PBM contracts for inflated drug prices
• Conway countered that high hospital and pharmaceutical costs, not just PBMs, are the core drivers of the problem
• Despite the confrontational exchange, both men acknowledged each other's contributions while disagreeing on root causes and solutions

The article discusses the challenges and stagnation in healthcare AI, highlighting that the industry is significantly behind other sectors despite advancements in technology. It also emphasizes the need for transparency and innovation in healthcare, mentioning ongoing investigations into unethical practices by certain organizations.

• Healthcare's core incentive problem: treating illness is more profitable than preventing it, which actively discourages AI innovation aimed at improving outcomes
• Many hyped claims of AI outperforming human doctors in diagnostics don't hold up under scrutiny
• The author's investigations into Commure and Mayo Clinic point to unethical practices warranting transparency and accountability
• A complex, fragmented system, entrenched incumbents, and compliance-focused regulation are structurally blocking healthcare AI progress

TrumpRx, a new public-private program launched by the Trump administration in partnership with Pfizer, aims to offer direct-to-consumer drug sales at significantly reduced prices. While it seeks to provide discounts on medications, experts suggest it closely resembles existing DTC models like Cost Plus Drugs and may not substantially impact the majority of patients who rely on insurance for prescriptions.

• TrumpRx is a new public-private drug pricing program launched by the Trump administration with Pfizer offering direct-to-consumer sales at reduced prices.
• Experts say it closely resembles existing DTC models like Mark Cuban's Cost Plus Drugs rather than being a novel approach.
• Since most patients rely on insurance rather than paying cash for prescriptions, the program likely won't have a major impact on the majority of drug purchasers.

ClearCare Online's API documentation outlines the importance of digital data sharing in healthcare, detailing various data types, including simple and complex types, as well as the authentication flow using OAuth 2.0. It also highlights enhancements and bug fixes in recent releases to improve data management and compliance with FHIR standards.

• The API uses OAuth 2.0 for authentication, requiring clients to obtain and refresh access tokens for secure data exchange
• Data types are split into simple (strings, dates, booleans) and complex (nested objects like client or caregiver records) to structure API responses
• Recent releases add enhancements and bug fixes aimed at improving data management and aligning the API with FHIR interoperability standards